Cargando…
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of warfarin therapy after a first venous thromboembolic event is however a matter of some controversy and many questi...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632629/ https://www.ncbi.nlm.nih.gov/pubmed/19014462 http://dx.doi.org/10.1186/1740-2557-5-6 |